TB-500 Deep-Dive
Also known as: Thymosin Beta-4 · TB4 Fragment · Tβ4
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino-acid peptide. Researchers investigate its actin-binding properties, which are proposed to drive cell migration, blood-vessel formation, and tissue remodeling at sites of injury. The compound is investigated for systemic recovery research and connective-tissue applications.
Plasma Half-Life
~48 hours
Logarithmic scale · 2.0 d mapped
Tissue Residency
Functional duration 2–4 days post-administration in animal models
Quick Facts
- Typical dose
- 2–2.5 mg, 1–2x weekly
- Range
- 1.5 mg – 5 mg per dose (loading vs maintenance)
- Route
- Subcutaneous or intramuscular. Loading phase typically 2x weekly, maintenance 1x weekly or every 10–14 days.
- Cycle pattern
- Common practitioner pattern: 4–6 week loading phase (2x weekly), then 4–8 week maintenance (1x weekly or biweekly). Some protocols cycle off 4 weeks between blocks.
- Primary evidence tier
- Expert
Mechanism of Action
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino-acid peptide. Researchers investigate its actin-binding properties, which are proposed to drive cell migration, blood-vessel formation, and tissue remodeling at sites of injury. The compound is investigated for systemic recovery research and connective-tissue applications.
Researchers investigate TB-500 in the broader context of the Healingcompound class. The compound's proposed relationship to underlying physiology is typically framed against the Inflammation axis — a framework DoseCraft uses to organize research priorities across the 90+ compound library.
In the practitioner corpus that trains the DoseCraft AI copilot, TB-500's mechanism is repeatedly cross-referenced against its pharmacokinetic profile (plasma half-life ~48 hours) because dosing cadence, stack selection, and cycling structure all derive from the PK window. This is the core difference between a static calculator and a PK-aware reasoning layer.
Pharmacokinetics
Plasma Half-Life (Logarithmic)
~48 hours
Logarithmic scale · 2.0 d mapped
Tissue Residency
Functional duration 2–4 days post-administration in animal models
TB-500 has a plasma half-life of approximately ~48 hours. This window is the primary driver of every downstream protocol decision: dosing frequency, stack overlap, cycling length, and the observable duration of subjective response.
Beyond the plasma window, functional duration 2–4 days post-administration in animal models. This tissue-residency or functional-duration behavior is why practitioner protocols often deviate from what raw plasma half-life alone would suggest.
In the DoseCraft PK model, this compound is mapped onto the same decay-curve framework that powers the half-life visualizer in the app — every stack built in the Protocol Builder factors in the half-life overlap of TB-500alongside any co-administered compounds. Static calculators elsewhere ignore this; it's why the practitioner corpus consistently flags half-life literacy as a top-three safety variable.
From real clinicians · not PubMed abstracts
Practitioner Protocols
Practitioner Corpus
Sourced from 10,000+ hours of clinician-validated protocols, bloodwork reviews, and cycle audits. Not PubMed. Not Reddit.
Clinicians who run high-volume peptide practices report TB-500 as the long-half-life partner to BPC-157 in nearly all recovery-research protocols. The ~48-hour plasma half-life enables 1–2x weekly dosing — a major practitioner advantage over the multiple-daily BPC-157 schedule. In protocol audits we've reviewed, the loading-phase pattern (2x weekly for 4–6 weeks, then weekly maintenance) consistently appears across independent practitioner sources.
Dosing
2–2.5 mg, 1–2x weekly
Subcutaneous or intramuscular. Loading phase typically 2x weekly, maintenance 1x weekly or every 10–14 days.
Cycle
Common practitioner pattern: 4–6 week loading phase (2x weekly), then 4–8 week maintenance (1x weekly or biweekly). Some protocols cycle off 4 weeks between blocks.
Evidence Breakdown
Every finding about TB-500is categorized across three independent evidence lanes. You always know what research tier you’re acting on.
- Recombinant TB4 has been studied in human trials for corneal injury and cardiac applications; synthetic TB-500 fragment lacks comparable human trial data.
- Strong practitioner consensus as the long-half-life recovery-research partner to BPC-157. Loading-then-maintenance dosing pattern is near-universal in audited protocols.
- Emerging research investigates dermal and hair-follicle applications; community protocol logs report systemic recovery responses with weekly dosing.
Cycling & Stack Considerations
Cycling Protocol
Common practitioner pattern: 4–6 week loading phase (2x weekly), then 4–8 week maintenance (1x weekly or biweekly). Some protocols cycle off 4 weeks between blocks.
Common Stacks
- •TB-500 + BPC-157 (the canonical recovery pairing)
- •TB-500 + GHK-Cu (skin / connective tissue stack)
- •TB-500 + CJC-1295/Ipamorelin (recovery + GH axis)
Interactions & Overlap
- •BPC-157 (canonical recovery co-administration; no documented adverse interaction)
- •GHK-Cu (often stacked for connective-tissue research)
- •Growth-hormone-axis peptides (mechanistically complementary)
Honest negatives · the part other trackers skip
Contraindications & Watch-Outs
Research Watch-Outs
- Active malignancy — proliferative mechanisms theoretically contraindicated
- Pregnancy and lactation — no human safety data
- Acute infectious processes — practitioner caution due to immune-modulating profile
TB-500 FAQs
What is the half-life of TB-500?
TB-500 has an approximate 48-hour plasma half-life, with functional duration extending 2–4 days post-administration in animal models. This long half-life is the primary reason practitioner protocols can use 1–2x weekly dosing rather than daily.
What is the typical TB-500 dose?
The most common practitioner protocol uses 2–2.5 mg per dose. Loading phases typically run 2x weekly for 4–6 weeks; maintenance phases drop to 1x weekly or every 10–14 days.
TB-500 vs BPC-157 — which is better?
Practitioner consensus is that they are complementary, not competitive. BPC-157 has a short plasma half-life (~30 min) and is dosed daily; TB-500 has a long half-life (~48 hr) and is dosed weekly. Most recovery-research protocols stack the two.
How long does TB-500 take to work?
In protocol audits we've reviewed, subjective response is typically reported within the first 2–3 weeks of a loading phase. Full protocol cycles run 8–12 weeks before assessment.
Is TB-500 the same as Thymosin Beta-4?
TB-500 is a synthetic fragment of the full 43-amino-acid Thymosin Beta-4 peptide. The fragment retains the actin-binding sequence proposed to drive the recovery research interest.
What are TB-500 side effects?
The practitioner safety profile is generally regarded as favorable; transient injection-site reactions and mild lethargy during loading phases are the most commonly reported observations. No long-term human safety data exists.
Can TB-500 be used alone or only stacked?
Both protocols exist. Solo TB-500 protocols are common when long-half-life convenience is the priority. The TB-500 + BPC-157 stack is the dominant pattern when broad-spectrum recovery research is the goal.
Related Compounds
Track your TB-500 protocol in DoseCraft
The PK-aware protocol builder models ~48 hours decay, checks stack overlap, and flags contraindications — built on the same practitioner corpus that powers this page.
See pricingFor research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Content on this page is educational and does not constitute medical advice, dosing guidance, or a protocol recommendation. Consult a qualified clinician before undertaking any research involving peptide compounds.